Nymox Pharmaceutical Corp Beta
Was ist das Beta von Nymox Pharmaceutical Corp?
Beta von Nymox Pharmaceutical Corp ist 0.00
Was ist die Definition von Beta?
BETA gibt an, ob eine Aktie mehr oder weniger schwankungsanfällig ist als der Gesamtmarkt. Ein Beta von weniger als 1 zeigt an, dass die Aktie weniger schwankungsanfällig ist als der Markt, während ein Beta von mehr als 1 anzeigt, dass die Aktie mehr schwankungsanfällig ist. Die Schwankungsanfälligkeit wird als Schwankung des Preises um den Mittelwert gemessen.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Nymox Pharmaceutical Corp
Was macht Nymox Pharmaceutical Corp?
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Unternehmen mit beta ähnlich Nymox Pharmaceutical Corp
- Vision Marine Technologies hat Beta von 0.00
- Ely Gold Royalties hat Beta von 0.00
- Glacier Lake Resources hat Beta von 0.00
- Magnum Mining and Exploration hat Beta von 0.00
- Africa Opportunity Fund hat Beta von 0.00
- Fulcrum Utility Services hat Beta von 0.00
- Nymox Pharmaceutical Corp hat Beta von 0.00
- Gullewa hat Beta von 0.00
- S.A.L. Steel hat Beta von 0.00
- Andina Acquisition III hat Beta von 0.00
- Andina Acquisition III hat Beta von 0.00
- Brilliant Acquisition hat Beta von 0.00
- Indokem hat Beta von 0.00